 MONT-SAINT-GUIBERT, Belgium, Nov. 10, 2020 GLOBE NEWSWIRE -- Celyad Oncology SA Euronext Nasdaq: CYAD, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell CAR T therapies for cancer, today announced an update on its operational developments for the third quarter ended September 30, 2020. 